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Determination of the iron state (Fe2+ or Fe3+) and content of iron in commercial pharmaceutical products
containing ferrous fumarate FeC4H2O4 was made by the Mössbauer spectroscopy and X-ray fluorescence method.
Also, influence of thermal treatment on stability of ferrous fumarate in selected medicaments has been investigated.
The investigated samples were annealed in definite temperature: 373, 473, and 573 K for 5 h. Room temperature
Mössbauer spectra of initial samples gave clear evidence that two phases of iron were presented. The major com-
ponent was connected with ferrous fumarate with a contribution from ≈85% to ≈50%, depending on investigated
medicaments. Ferrous fumarate was stable up to annealing temperature 473 K. Above this temperature significant




Iron plays a very important role in the living sys-
tems. It is an integral part of many proteins, enzymes
and minerals that work with other substances to cre-
ate hemoglobin. During pregnancy and after birth, a
woman’s requirement for iron increases. This require-
ment increases significantly during pregnancy as mater-
nal blood volume increases and a baby’s blood system is
developing. Absorption of iron from food requires recog-
nition of the chemical form of iron by gut receptors. Both
shape and charge are important in the recognition pro-
cess. To be absorbed, dietary iron must be in its ferrous
form, which is soluble, unless the Fe3+ ion is chelated [1].
Therefore, the knowledge of the iron valence state in
medicaments is very important because it may be related
to the effect and toxicity of such pharmaceutical product.
Many medicaments used in daily life have a reduced
therapeutic effect because of their poor physico-chemical
characteristics. Poor solubility, especially of the drugs
used in the long-term treatment, can lead to increased
number of side effects or does not give any expected ef-
fects. Preparations based on iron Fe2+ fumarate are now
widely used because of its good properties such as good
adsorption affinity in the body, low toxicity and mini-
mal side effects, pure iron Fe2+ fumarate is a compound
stable up to temperature 570 K [2]. The Mössbauer spec-
troscopy is the most sensitive technique for the analysis
of iron state [3, 4]. Hyperfine parameters of 57Fe from the
Mössbauer spectra like isomer shift (Is) and quadrupole
splitting (Qs) give information about the iron electron
structure, valence and spin state of iron. The content




In this work content of iron in selected medicaments
has been determined. We also checked how production
process affects the content of iron Fe2+ in ferrous fu-
marate in investigated dietary supplements. Used every
day medicaments are stored in various physical condi-
tions. Therefore, the influence of thermal treatment on
stability of ferrous fumarate contained in dietary supple-
ments for women using the Mössbauer effect technique
was studied.
2. Experimental procedure
The following samples of commercially available di-
etary supplements for pregnant women were cho-
sen for this study: Prenatal®Classic (Furitan’s Pride
Inc., USA), Pregnacare® Original (Vitabiotics Ltd.
United Kingdom) and Falvit® (Jelfa, Poland). All the in-
vestigated dietary supplements contained iron in the form
of ferrous fumarate FeC4H2O4. The studied dietary sup-
plements contained different amount iron per one tablet:
60 mg in Prenatal® Classic, 17 mg in Pregnacare® Orig-
inal and 14 mg in Falvit®.
The chemical composition was determined using X-ray
fluorescence (XRF) ZSX Primus II Rigaku spectrometer.
The spectrometer, equipped with the 4 kW, 60 kV Rh-
anode and wavelength dispersion detection system, al-
lowed for the analysis of the elements from Be to U. No
external standard were necessary, only the internal stan-
dards coupled with the fundamental parameters method
(theoretical relationship between measured X-ray inten-
sities and the concentrations of elements in the sample)
were implemented.
The 57Fe Mössbauer spectra were recorded at room
temperature using a constant acceleration spectrometer
with 57Co:Cr source, a multichannel analyzer with 1024
channels and linear arrangement of the 57Co source, an
absorber and a detector. The values of Is and Qs for
all identified subspectra were determined with reference
to the centroid of the spectrum of a standard α-Fe foil.
These Mössbauer spectra were calculated by means of
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a discrete analysis (few doublets and a Zeeman sextet).
The Mössbauer investigations were made on powdered
samples and were performed at room temperature. Be-
fore the measurements all the samples were annealed in
air atmosphere in static conditions by 5 h in definite tem-
perature: 373, 473, and 573 K.
3. Result and discussion
Results of XRF analysis showed that examined medica-
ments contain quantity of iron without much difference
with that given by the manufacture. Prenatal®Classic
contains 62 mg, Pregnacare® Original 15 mg and Falvit®
14 mg.
Fig. 1. Mössbauer spectra of Prenatal® Classic for the
initial sample and after annealing at 373 K and 473 K.
Fitted subspectra are presented in the spectra.
Fig. 2. As Fig. 1 for Falvit®.
The Mössbauer spectra of investigated medicaments
before and after annealing process are presented in
Figs. 1–4. Hyperfine parameters connected with par-
ticular subspectra are listed in Table I with experimen-
tal errors smaller than 5%. Previous Mössbauer data
for ferrous fumarate were: Is in range from 1.16 mm/s
to 1.24 mm/s and Qs in range from 2.18 mm/s to
2.24 mm/s [3, 5–7]. Hyperfine parameters of main
component of all the investigated supplements corre-
spond to ferrous fumarate. The content of FeC4H2O4 in
Prenatal® Classic is about 85%, in Falvit® 65% and only
50% in Pregnacare® Original. Apart from main com-
ponent additional components related to the high spin
ferric compound were observed in the Mössbauer spec-
tra. Ferric ions accompanying ferrous iron compound
contained in dietary supplements were also observed by
other authors [3, 5–8]. All observed ferric components
have similar hyperfine parameters, but their content is
different in investigated medicaments. Existence of these
ferric ions can be a result of oxidations of Fe2+ ions in
ferrous fumarate to Fe3+ ions in production process used
by different producers.
Fig. 3. As Fig. 1 for Pregnacare® Original.
Fig. 4. Mössbauer spectra of investigated dietary su-
plements: Prenatal® Classic, Falvit®, Pregnacare®
Oryginal obtained after annealing at 573 K. Fitted sub-
spectra are presented in the spectra.
Annealing process of all the medicaments at the tem-
perature 373 K leads to homogenization of investigated
compound, which is reflected in narrowing of width of
absorption lines. It can suggest that iron fumarate was
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TABLE I
Mössbauer parameters of the investigated dietary supple-
ments measured at room temperature before and after an-
nealing process. Is — isomer shift [mm/s], Qs — quadru-
ple splitting [mm/s], H — hyperfine magnetic field [T], G
— line width [mm/s], A – relative intensity [%]. Com-
pound: FF — ferrous fumarate, FH — ferric high spin, H
— hematite.
Is Qs H G A comp.
Prenatal® Classic
RT
1.20 2.23 - 0.28 85 FF
0.18 0.41 - 0.28 15 FH
373 K
1.22 2.25 - 0.30 82 FF
0.18 0.39 - 0.25 18 FH
473 K
1.21 2.24 - 0.28 79 FF
0.19 0.43 - 0.30 21 FH
573 K
0.39 0.80 - 0.30 68 FH
0.12 0.68 - 0.25 22 FH
0.39 0.25 50 0.35 10 H
Falvit®
RT
1.23 2.23 - 0.32 65 FF
0.19 0.42 - 0.28 35 FH
373 K
1.21 2.22 - 0.30 61 FF
0.19 0.40 - 0.28 39 FH
473 K
1.23 2.23 - 0.36 66 FF
0.18 0.39 - 0.32 34 FH
573 K
1.19 2.28 - 0.20 11 FF
0.85 0.26 - 0.30 16 FH
0.13 0.49 - 0.50 73 FH
Pregnacare®Original
RT
1.24 2.16 - 0.41 51 FF
0.18 0.42 - 0.36 49 FH
373 K
1.23 2.21 - 0.28 51 FF
0.19 0.41 - 0.28 49 FH
473 K
1.21 2.80 - 0.34 14 FF
1.22 2.05 - 0.50 39 FF
0.22 0.45 - 0.54 49 FH
573 K
0.20 0.53 - 0.60 68 FH
0.50 0.65 - 0.50 22 FH
0.38 0.30 51 0.70 10 H
prepared in some inclusion complexes. They are increas-
ingly used in the formulations of pharmaceutical prod-
ucts to ensure their safer application and can have the
amorphous nature of the structures [2, 9, 10]. After an-
nealing at 473 K, broadening of the absorption line for
all the components on the Mössbauer spectra of Falvit®
and Prenatal® Classic was observed. In the spectrum
of Pregnacare® Original two doublets connected with
FeC4H2O4 were observed. However, these doublets had
different values of quadrupole splitting, which suggests
that Fe2+ ions occupy two different iron sites with a
slightly different symmetry. This can indicates on some
interaction between iron fumarate and inclusion com-
plexes [2]. Above 473 K temperature significant oxida-
tion of Fe2+ to Fe3+ was observed. In the Mössbauer
spectra of Prenatal® Classic and Pregnacare® Original
only the doublets connected with ferric ions and small
contribution of magnetic component, which was identi-
fied as hematite [11], were observed. Small content of
ferrous fumarate, about 11%, in Falvit® was observed
after heating in 573 K.
4. Conclusions
From the above results we may conclude the follow-
ing. The XRF method results confirm quantity of iron
provided by the manufacturer of the investigated phar-
maceutical products.
The results of the applications of the Mössbauer spec-
troscopy to study various industrial samples of dietary
supplements containing iron ions demonstrate wide pos-
sibilities of this technique. 57Fe hyperfine parameters of
the studied pharmaceuticals indicate the existence of fer-
rous fumarate. However, the content of this compound in
some investigated medicaments and thus Fe2+ ions con-
tent cannot be satisfactory for a consumer. Obtained
Mössbauer spectra indicated the presence of additional
ferric compound with a different relative contribution in
each supplement. Hyperfine parameters of ferric doublets
are almost the same in each investigated pharmaceutical
product. It can suggest that this component is closely
connected with ferrous fumarate FeC4H2O4 and can be
the result of production process effects. Ferrous fumarate
contained in dietary supplements is a stable compound
up to heating temperature 473 K which is important
news for storage conditions of investigated pharmaceu-
tical products.
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